Not Yet RecruitingNot Applicable

Suprapubic Transverse Incision With Rectus Release for Upper Peritoneal Access): A Novel Dual-Plane Technique for Abdominal Wall Incision in Complex Gynecological Surgery

50 participantsStarted 2026-02-01

Plain-language summary

This study aims to evaluate the clinical effectiveness, anatomical benefits, and postoperative outcomes of the STIRRUP incision (Suprapubic Transverse Incision with Rectus Release for Upper Peritoneal Access) by comparing outcomes with historically established benchmarks and published data from traditional abdominal wall incisions used in complex gynecologic surgery.

Who can participate

Age range18 Years – 65 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Female patients aged 18-65 years
✓. Indication for open gynecologic surgery for benign or borderline pelvic or abdominopelvic masses
✓. Body Mass Index (BMI) ≥ 18 kg/m²
✓. Willing and able to provide informed consent and attend follow-up
✓. Mass size between 15-30 cm, which is considered optimal for the STIRRUP (Suprapubic Transverse Incision with Rectus Release for Upper Peritoneal access) technique due to the balance between exposure and minimal morbidity

Exclusion criteria

✕. Malignant tumors requiring upper abdominal visceral resection (liver, spleen, diaphragm)
✕. Emergency surgery
✕. Previous complex abdominal wall reconstruction with mesh
✕. Contraindication to general anesthesia
✕. Masses extending to the xiphisternum or measuring \>30 cm
✕. Cases requiring supracolic omentectomy
✕. Planned lymphadenectomy (especially if comprehensive para-aortic lymph node dissection is required )
✕. Supramesocolic tumor extension or malignant ovarian tumors requiring hepatic resections, splenectomy, and diaphragmatic resection

What they're measuring

Postoperative seroma formation

Timeframe: within the postoperative or follow-up period (6 months)

Trial details

NCT IDNCT07373886

SponsorCairo University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-11-01

View on ClinicalTrials.gov More Post-Op Complication trials